Pharmalot

Pharmalot

Pharmalittle: Most Americans worry about drug prices, not Medicare for All; FDA remains divided over a drug

By Ed Silverman

Pharmalot

Civica Rx teams with Blue Cross Blue Shield to widen its alternative market for generics

By Ed Silverman

Pharmalot

European Court adviser deals Glaxo a setback in ‘pay-to-delay’ case

By Ed Silverman

Pharmalot

European court upholds controversial EMA transparency rules for clinical trial data

By Ed Silverman

Pharmalot

Pharmalittle: Connecticut lawmakers look to cap insulin prices; Glaxo halts Excedrin production

By Ed Silverman

Pharmalot

As prescribing for ADHD stimulants rose, so did industry payments to doctors

By Ed Silverman

Pharmalot

Pharma is making some effort to fight superbugs, but progress is ‘patchy’

By Ed Silverman

Pharmalot

Pharmalittle: Indian drug makers receive most FDA warning letters; most clinical trial results go unreported

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: FTC member favors Medicare negotiation on drug prices; BioMarin weighs pricing world’s most expensive drug

By Elizabeth Cooney

Pharmalot

Lilly exec says ‘there are no villains’ in the high-priced insulin market

By Ed Silverman

Pharmalot

Pharmalittle: Tension in the Verily-Dexcom tango; not so fast on the Pfizer-GSK spinoff

By Elizabeth Cooney

Pharma

Pharmalittle: FDA acts faster but with less proof; Democratic debaters double down on drug pricing

By Elizabeth Cooney

Pharmalot

Pharmalittle: Roche plans aggressive SMA drug pricing; where are those clinical trial results?

By Elizabeth Cooney

Pharmalot

Pharmalittle: AstraZeneca fish oil pill flops; boom in biopharma dealmaking predicted for 2020

By Elizabeth Cooney

Pharmalot

High cost of multiple sclerosis medicines is forcing many patients to take ‘drastic actions’

By Ed Silverman

Pharmalot

Supreme Court will review an Arkansas law governing pharmacy benefit managers

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Combining antibiotics may cause resistance; Lilly moves into dermatitis market with $1.1 billion deal

By Ed Silverman

Pharmalot

Bristol-Myers and Sanofi accuse Hawaii of violating their free speech rights

By Ed Silverman

Pharmalot

California plans to sell its own generic drugs in hopes of lowering costs

By Ed Silverman

Pharmalot

Pharmalittle: More companies recall heartburn tablets; Merck’s Keytruda wins another cancer approval

By Ed Silverman

Pharmalot

They did what? Celgene backs out of a $55 million deal to settle claims of thwarting generics

By Ed Silverman

Pharmalot

Patient groups say Brazilian proposal to change patent reviews would favor pharma

By Ed Silverman

Pharmalot

Pharmalittle: Execs vow to place patients ahead of profits; conservatives like Republican drug pricing bill

By Ed Silverman

Another patient charity settles charges it helped drug makers pay Medicare kickbacks

Up and down the ladder: The latest comings and goings

Pharmalittle: Drug makers spent $120 million lobbying Congress in 2019; more investors are bullish on Biogen’s Alzheimer drug

Many patient groups have deep ties to pharma but fail to disclose backing

Pharmalittle: Most Americans worry about drug prices, not Medicare for All; FDA remains divided over a drug

Civica Rx teams with Blue Cross Blue Shield to widen its alternative market for generics

European Court adviser deals Glaxo a setback in ‘pay-to-delay’ case

European court upholds controversial EMA transparency rules for clinical trial data

Pharmalittle: Connecticut lawmakers look to cap insulin prices; Glaxo halts Excedrin production

As prescribing for ADHD stimulants rose, so did industry payments to doctors

Pharma is making some effort to fight superbugs, but progress is ‘patchy’

Pharmalittle: Indian drug makers receive most FDA warning letters; most clinical trial results go unreported

Up and down the ladder: The latest comings and goings

Pharmalittle: FTC member favors Medicare negotiation on drug prices; BioMarin weighs pricing world’s most expensive drug

Lilly exec says ‘there are no villains’ in the high-priced insulin market

Pharmalittle: Tension in the Verily-Dexcom tango; not so fast on the Pfizer-GSK spinoff

Pharmalittle: FDA acts faster but with less proof; Democratic debaters double down on drug pricing

Pharmalittle: Roche plans aggressive SMA drug pricing; where are those clinical trial results?

Pharmalittle: AstraZeneca fish oil pill flops; boom in biopharma dealmaking predicted for 2020

High cost of multiple sclerosis medicines is forcing many patients to take ‘drastic actions’

Supreme Court will review an Arkansas law governing pharmacy benefit managers

Up and down the ladder: The latest comings and goings

Pharmalittle: Combining antibiotics may cause resistance; Lilly moves into dermatitis market with $1.1 billion deal

Bristol-Myers and Sanofi accuse Hawaii of violating their free speech rights

California plans to sell its own generic drugs in hopes of lowering costs

Pharmalittle: More companies recall heartburn tablets; Merck’s Keytruda wins another cancer approval

They did what? Celgene backs out of a $55 million deal to settle claims of thwarting generics

Patient groups say Brazilian proposal to change patent reviews would favor pharma

Pharmalittle: Execs vow to place patients ahead of profits; conservatives like Republican drug pricing bill